Arcturus therapeutics announces second quarter 2022 financial update and pipeline progress

San diego--(business wire)---- $arct #clinicaltrial--arcturus therapeutics holdings inc. (the “company”, “arcturus”, “arcturus therapeutics”, nasdaq: arct), a global, late-stage clinical messenger rna medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced its financial results for the second quarter ended june 30, 2022, and provided corporate updates. “arcturus continues to demonstrate increasing value of our
ARCT Ratings Summary
ARCT Quant Ranking